Loading...
Adynxx, Inc.
ADYX•PNK
HealthcareBiotechnology
$0.00
$0.00(0.00%)
Adynxx, Inc. (ADYX) Stock Overview
Explore Adynxx, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ADYXStats details for ADYX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ADYXAnalyst Recommendations details for ADYX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
CEO
Mr. Richard Orr Esq., J.D.
Employees
6
Headquarters
100 Pine Street, San Francisco, CA
Founded
1998